D
David Sanchez-Migallon Guzman
Researcher at University of California, Davis
Publications - 224
Citations - 6920
David Sanchez-Migallon Guzman is an academic researcher from University of California, Davis. The author has contributed to research in topics: Population & Amazona ventralis. The author has an hindex of 36, co-authored 201 publications receiving 5848 citations. Previous affiliations of David Sanchez-Migallon Guzman include Royal Free Hospital & San Francisco General Hospital.
Papers
More filters
Journal ArticleDOI
Clinical picture and treatment of 2212 patients with common variable immunodeficiency
Benjamin Gathmann,Nizar Mahlaoui,Laurence Gérard,Eric Oksenhendler,Klaus Warnatz,I. Schulze,Gerhard Kindle,Taco W. Kuijpers,Rachel T. van Beem,David Sanchez-Migallon Guzman,Sarita Workman,Pere Soler-Palacín,Javier de Gracia,Torsten Witte,Reinhold E. Schmidt,Jiri Litzman,Eva Hlaváčková,Vojtech Thon,Michael Borte,Stephan Borte,Stephan Borte,Dinakantha S. Kumararatne,Conleth Feighery,Hilary Longhurst,Matthew Helbert,Anna Szaflarska,Anna Sediva,Bernd H. Belohradsky,Alison Jones,Ulrich Baumann,Isabelle Meyts,Necil Kutukculer,Per Wågström,Nermeen Galal,Joachim Roesler,Evangelia Farmaki,Natalia Zinovieva,Peter Ciznar,Efimia Papadopoulou-Alataki,Kirsten Bienemann,Sirje Velbri,Z. Panahloo,Bodo Grimbacher,Bodo Grimbacher +43 more
TL;DR: In this article, the authors analyzed the clinical presentation, association between clinical features, and differences and effects of immunoglobulin treatment in Europe for Common Variable Immunodeficiency (CVID) patients.
Journal ArticleDOI
Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale.
Thomas P. Giordano,David Sanchez-Migallon Guzman,Richard A.F. Clark,Edwin D. Charlebois,David R. Bangsberg +4 more
TL;DR: A visual analogue scale to assess adherence was performed as well as a more complicated 3-day recall instrument in this diverse population of HIV-infected patients, and may be useful in routine patient care.
Journal ArticleDOI
Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness.
David R. Bangsberg,Edward P. Acosta,Reena Gupta,David Sanchez-Migallon Guzman,Elise D. Riley,P. Richard Harrigan,Neil Parkin,Steven G. Deeks +7 more
TL;DR: NNRTI resistance was more common than PI resistance at low levels of adherence, and class-specific adherence–resistance relationships are associated with the relative replicative capacity of drug-resistant versus wild-type variants to replicate in the presence of clinically relevant drug levels.
Journal ArticleDOI
Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease
Dhruv S. Kazi,Andrew E. Moran,Pamela G. Coxson,Joanne Penko,Daniel A. Ollendorf,Steven D. Pearson,Jeffrey A. Tice,David Sanchez-Migallon Guzman,Kirsten Bibbins-Domingo +8 more
TL;DR: Using PCSK9 inhibitor use in patients with heterozygous FH or ASCVD did not meet generally acceptable incremental cost-effectiveness thresholds and was estimated to increase US health care costs substantially, compared with initiating statins in all statin-tolerant individuals who are not currently using statins.
Journal ArticleDOI
High levels of adherence do not prevent accumulation of HIV drug resistance mutations.
David R. Bangsberg,Edwin D. Charlebois,Robert M. Grant,Mark Holodniy,Steven G. Deeks,Sharon Perry,Kathleen Conroy,Richard A.F. Clark,David Sanchez-Migallon Guzman,Andrew R. Zolopa,Andrew R. Moss +10 more
TL;DR: Increasing rates of viral suppression at high levels of adherence is balanced by increasing rates of drug resistance among viremic patients, which will not prevent population levels ofdrug resistance.